SCHEMBL5545433

SCHEMBL5545433

N#Cc1ccc(Nc2cc(C(N)=O)ccn2)cc1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 3/20 0.48
▸ SGMS2 Q8NHU3 1/20 0.46
▸ FNTA P49354 1/20 0.45
▸ FNTB P49356 1/20 0.45
▸ PGGT1B P53609 1/20 0.45
▸ PPIA P62937 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5550158 0.86 XDH (0.51) XDHSGMS2FNTAFNTBPGGT1B
SCHEMBL5544745 0.84 XDH (0.49) XDHSGMS2FNTAFNTBPGGT1B
SCHEMBL5546967 0.81 XDH (0.52) XDHFNTAFNTBPGGT1B
SCHEMBL5545418 0.80 PPIA (0.49) FNTAFNTBPGGT1BPPIA
SCHEMBL5551550 0.80 XDH (0.46) XDHFNTAFNTBPGGT1BPPIA
SCHEMBL551997 0.74 FNTA (0.53) XDHSGMS2FNTAFNTBPGGT1B
SCHEMBL14584976 0.74 XDH (0.50) XDHFNTAFNTBPGGT1B
SCHEMBL13887201 0.74 C5AR1 (0.51) XDHFNTAFNTBPGGT1B
SCHEMBL250412 0.74 ROCK1 (0.56) —
SCHEMBL14402358 0.73 XDH (0.49) XDHFNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1442019-B1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2007-10-10 — — EP claimed
US-20050176713-A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors FREYNE EDDY JEAN E (BE) 2005-08-11 — — US claimed
EP-1442019-A1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-08-04 — — EP claimed
WO-2003037869-A1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2003-05-08 — — WO claimed
EP-1442019-B1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2007-10-10 — — EP disclosed
US-7183288-B2 Amide derivatives as glycogen synthase kinase 3-β inhibitors FREYNE EDDY JEAN EDGARD 2007-02-27 — — US disclosed
US-20050176713-A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors FREYNE EDDY JEAN E (BE) 2005-08-11 — — US disclosed
EP-1442019-A1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2004-08-04 — — EP disclosed
WO-2003037869-A1 AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2003-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176713-A1 Amide derivatives as glycogen synthase kinase 3-beta inhibitors GSK3B, GSK3A, PHKG1 XDH 1032/4885SGMS2 2967/4885FNTA 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback